Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2016-07-19 Capital/Financing Update
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Retail Entitlement Offer completion and scale back policy 1
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 20 July 2016 from Mayne Pharma Group Limited regarding the successful completion of a Retail Entitlement Offer, raising approximately A$254 million. It details the uptake of entitlements by retail shareholders, allocation under a Top-Up Offer, refund policies, and the expected trading date of new shares. There are no financial statements or detailed financial analysis included, only information about the completion of a capital raising event. The document is relatively short (2399 characters) and serves as a formal announcement of financing activity rather than a full financial report or detailed investor presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2016-07-19 English
Change to option exercise price and Appendix 3B 11 pages 930.3KB
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement from Mayne Pharma Group Limited regarding changes to employee options exercise prices following an entitlement offer, including a summary table of options and an Appendix 3B form. Appendix 3B is a standard ASX form used for new issue announcements, application for quotation of additional securities, and agreements related to securities issuance. The document includes detailed information about securities issued, exercise prices, expiry dates, and compliance with ASX listing rules. It is not a financial report, earnings release, or management discussion but rather a regulatory announcement about securities issuance and capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive filing about capital changes.
2016-07-14 English
Change of Director's Interest Notice 2 pages 383.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in shareholding, including the number of shares held before and after the change, the nature of the transaction, and the value of shares acquired. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document length is short and focused solely on this transaction, with no financial statements or broader company information. Therefore, the correct classification is Director's Dealing (DIRS).
2016-07-12 English
Section 708A notice 1 page 303.8KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of shares by Mayne Pharma Group Limited. It details the issuance of 191,300,000 fully paid ordinary shares to institutional shareholders and compliance with relevant sections of the Corporations Act. The content focuses on a capital raising event and legal compliance notice related to share issuance, not a full financial report or earnings release. The document length is short (1458 characters) and it is a formal regulatory announcement about a capital transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-07-06 English
Change of Director's Interest Notices (x5) 10 pages 944.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in directors' relevant interests in securities, including the number of shares held before and after the change, the nature of the change, and consideration paid. The document is a formal notification of personal share transactions by company directors. It does not contain financial performance data, management discussion, or other report content. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is substantial and contains multiple such notices for different directors, reinforcing that it is a comprehensive insider trading report rather than a brief announcement or other filing type.
2016-07-06 English
ASX Notice - Accelerated Non Renounceable Entitlement Offer 2 pages 365.4KB
Capital/Financing Update Classification · 95% confidence The document is a notice from Mayne Pharma Group Limited regarding an accelerated non-renounceable entitlement offer to raise capital. It details the offer structure, timetable, settlement and trading issues, and contact information. The content focuses on a capital raising event and related procedural information. It is not a full financial report, earnings release, or management discussion. The document length is 4198 characters, which is relatively short and consistent with an announcement rather than a detailed report. The key subject is the entitlement offer, which is a financing activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2016-07-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.